aTYR PHARMA (ATYR) Net Cash Flow (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Net Cash Flow came in at -$1.2 million in Q1 2026, up 3.88% YoY from -$1.1 million in Q1 2025, and down 128.3% on a QoQ basis from $4.1 million in Q4 2025.
aTYR PHARMA (ATYR) Net Cash Flow (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Net Cash Flow data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 3.88% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$981000.0 (down 135.39% YoY) and the FY2025 annual result came in at -$1.0 million, up 91.45% from the prior year.
- Net Cash Flow slipped to -$1.2 million in Q1 2026, from $4.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $12.8 million in Q4 2023 to a low of -$16.0 million in Q1 2024.
- A 5-year average of $557470.6 and a median of -$321000.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow slumped 1012.43% — and 2025, when it surged 2375.39%.
- Tracing ATYR's Net Cash Flow over 5 years: stood at -$7.5 million in 2022, then jumped by 271.63% to $12.8 million in 2023, then tumbled by 102.96% to -$378000.0 in 2024, then jumped by 1188.89% to $4.1 million in 2025, then plunged by 128.3% to -$1.2 million in 2026.
- The last three Net Cash Flow figures came in at -$1.2 million (Q1 2026), $4.1 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 5.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.84 Mn |
| Jun 30, 2026 | 5.84 Mn |
| Mar 31, 2026 | -1.17 Mn |
| Mar 31, 2026 | -1.17 Mn |
| Dec 31, 2025 | 4.12 Mn |
| Dec 31, 2025 | 4.12 Mn |
| Sep 30, 2025 | -11.24 Mn |
| Sep 30, 2025 | -11.24 Mn |
| Jun 30, 2025 | 7.30 Mn |
| Jun 30, 2025 | 7.30 Mn |
| Mar 31, 2025 | -1.21 Mn |
| Mar 31, 2025 | -1.21 Mn |
| Dec 31, 2024 | -378,000.00 |
| Dec 31, 2024 | -378,000.00 |
| Sep 30, 2024 | 4.68 Mn |
| Sep 30, 2024 | 4.68 Mn |
| Jun 30, 2024 | -321,000.00 |
| Jun 30, 2024 | -321,000.00 |
| Mar 31, 2024 | -16.01 Mn |
| Mar 31, 2024 | -16.01 Mn |